Key result
Conduction system leadless pacemaker demonstrates 6-month electrical stability and sustained conduction capture.
Why the study?
The clinical value of leadless pacemakers for conduction system pacing depends on chronic electrical performance, device stability, and maintenance of conduction system capture, requiring longer-term follow-up.
Does a chronically-implanted leadless pacemaker designed for conduction system pacing maintain electrical stability, device stability, and conduction system capture at 6 months?
Observational
Does a chronically-implanted leadless pacemaker designed for conduction system pacing maintain electrical stability, device stability, and conduction system capture at 6 months?
This follow-up of a first-in-human experience assesses the critical 6-month chronic electrical performance and stability of a novel helix-fixation leadless pacemaker for conduction system pacing.
Requires vigilant chronic fixation monitoring for conduction system leadless pacemakers; extends 1-month data but leaves long-term durability open.
We recently reported the first-in-human experience with a chronically-implanted, helix-fixation leadless pacemaker designed for conduction system pacing (LPCSP; Aveir CSP, Abbott Inc), demonstrating feasibility and stable electrical performance through 1 month follow-up; notably, some early device dislodgement and changes in capture classification were observed.1 Because the clinical value of this technology depends on chronic electrical performance, device stability, and maintenance of conduction system capture, longer-term follow-up is important.
No takes yet. Share an insight, caveat, or question.
Reddy et al. (2026) reported an observational. Helix-fixation leadless pacemaker for conduction system pacing (LPCSP; Aveir CSP) was evaluated on Electrical stability, device stability, and maintenance of conduction system capture.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: